Similar to earlier studies that investigated fewer methylation markers, CIMP-H CRC were associated with older patient age, proximal location and mutations in BRAF and KRAS. Further investigations in large and independent population-based series are required to validate these findings and to assess the clinical utility of CIMP subgroups. The gene discussed is BRAF; the disease is colorectal carcinoma.